EC Number |
Inhibitors |
Structure |
---|
3.2.1.25 | (5R,6R,7S,8S)-5-(hydroxymethyl)-2-phenyl-5,6,7,8-tetrahydroimidazol[1,2-a]pyridine-6,7,8-triol |
- |
|
3.2.1.25 | (5S,6R,8R)-5-(hydroxymethyl)-2-(2-phenylethyl)-5,6,7,8-tetrahydroimidazo[1,2-a]pyridine-6,7,8-triol |
persuasive transition state mimic |
|
3.2.1.25 | (5S,6R,8R)-5-(hydroxymethyl)-2-(phenoxymethyl)-5,6,7,8-tetrahydroimidazo[1,2-a]pyridine-6,7,8-triol |
persuasive transition state mimic |
|
3.2.1.25 | (5S,6R,8R)-5-(hydroxymethyl)-2-[(phenylamino)methyl]-5,6,7,8-tetrahydroimidazo[1,2-a]pyridine-6,7,8-triol |
persuasive transition state mimic |
|
3.2.1.25 | 2-amino-2-deoxy-D-mannose |
- |
|
3.2.1.25 | 2-amino-2-deoxy-D-mannose |
competitive |
|
3.2.1.25 | 2-deoxy-2-fluoro-beta-D-mannosyl fluoride |
time-dependent inactivation through accumulation of a covalent 2-deoxy-2-fluoro-alpha-D-mannosyl-beta-mannosidase 2A enzyme intermediate |
|
3.2.1.25 | 2-deoxy-2-fluoro-beta-glycosyl fluorides |
in vivo inhibition |
|
3.2.1.25 | 4-nitrophenyl beta-D-thioglucoside |
competitive, adopts 4NP-S-Glc 3S5 or 1S3 conformations upon binding according to STD NMR and trNOESY experiments. QM modeling and docking, based on GLIDE scores, predicts that 4-nitrophenyl beta-D-thioglucoside preferentially binds in 1S3 geometries |
|
3.2.1.25 | 4-nitrophenyl beta-D-thiomannoside |
competitive, adopts 4C1 geometry upon binding according to STD NMR and trNOESY experiments. QM modeling and docking, based on GLIDE scores, predicts that 4-nitrophenyl beta-D-thiomannoside preferentially binds in 1S3 geometries |
|